Biotech · Public company · New York, NY, US
Ovid Therapeutics Inc.
Ticker OVID · SEC CIK 0001636651
Track this companyFree. Adds Ovid Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline2
- GaboxadolPhase 3 · Primary Disease or Condition Being Studied: Angelman Syndrome (AS)ClinicalTrials.gov · fetched Nov 12, 2026
- OV101 (gaboxadol)Phase 2 · Fragile X Syndrome (FXS)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of OV101 in Individuals With Angelman Syndrome (AS)PHASE3 · COMPLETED · started Sep 9, 2019ClinicalTrials.gov NCT04106557 · fetched Nov 12, 2026
- A Study of OV101 in Individuals With Fragile X SyndromePHASE2 · COMPLETED · started Sep 17, 2018ClinicalTrials.gov NCT03697161 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 20, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026